Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04136353
Title Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors University of Sydney
Indications

prostate adenocarcinoma

Therapies

Darolutamide

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.